Drug Recall: Erythromycin Ophthalmic Ointment Due to Manufacturing Deviations
Akorn, Inc. recalls 1.1 million tubes of Erythromycin Ophthalmic Ointment nationwide due to manufacturing deviations. The voluntary, Class II recall was initiated by the firm.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II voluntary recall due to CGMP deviations with no illnesses or injuries reported. Meets rubric criterion for 'voluntary precautionary recalls' lacking specific evidence of adverse health consequences.
Plain-English summary
Akorn, Inc. is recalling Erythromycin Ophthalmic Ointment USP 0.5% distributed nationwide in the United States. The product is supplied in 3.5g (1/8 oz) tubes (NDC 17478-070-35), with approximately 1.1 million tubes affected.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations during the manufacturing process. This is a Class II voluntary recall initiated by Akorn, Inc. in October 2022.
Multiple lot numbers with expiration dates ranging from October 2022 through April 2024 are included in this recall. The complete list of affected lot numbers and expiration dates is available from the FDA.
This is a prescription medication. Patients currently using this product should contact their healthcare provider or pharmacist regarding their supply and to determine whether an alternative medication should be used.
The recalled product
- Product
- ERYTHROMYCIN OPHTHALMIC OINTMENT USP 0.5%, Net Weight: 3.5g (1/8 oz) per tube, Rx Only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045. NDC: 17478-070-35
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic Medication
- Hazard
- Affected units
- 1,109,600
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: 0L58A
- EXP 10/31/2022
- 1B21A
- 1B31A
- EXP 1/31/2023
- 1C44A
- 1C58A
- 1C58B
- EXP 2/28/2023
- 1E13A
- 1E24A
- EXP 4/30/2023
- 1C57A
- 1G60A
- 1G62A
- 1G63A
- EXP 6/30/2023
- 1J34B
- 1J40A
- 1J21A
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 27 recalled by Akorn, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 27 products in this recall →Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · manufacturing deviation
See all →- HighBaxter Recalls Vancomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06